Background Dendritic cells (DC) are the most potent antigen-presenting cells (APC) and stimulators of T cells. Dendritic cells are also likely to be essential for the initiation of allergic immune responses in the lung. However, there are not many data on the presence of dendritic cells in the airways of patients with atopic asthma and on the effects of corticosteroid-treatment on such dendritic cells. Objective We investigated the distribution of dendritic cells in the bronchial epithelium and mucosa of 16 non-smoking atopic asthmatic patients and eight healthy control subjects using detailed immunohistochemistry (CDla, HLA-DR, L25 as markers for dendritic cells). Methods Eleven asthmatics were treated for 2.5 years with bronchodilators only and five with bronchodilators and inhaled beclomethasone dipropionate (BDP), 800^g daily. The patients were randomly sampled from a double-blind multicentre study. Re.sulis There were higher numbers of CDla' DC ( P -0.003). L25"^ DC ( Z' -0.002) and HLA-DR expression {P = 0.042) in the bronchial mucosa of asthmatic patients compared with healthy controls. After 2.5 years of treatment, we found a significant increase in fiow expiratory volume in I second (FEV,) (P = 0.009) and a significant decrease in hyperresponsiveness (PC^i histamine) (/" = 0.013) in the corticosteroid group {n = 5) compared with the bronchodilator group (« ^ 11). This dinical improvement in the corticosteroid-treated group was accompanied by significantly lower numbers of CDla^ DC (i* = 0.008), and HLA-DR expression (/*-0.028) in the bronchial mucosa than in the bronchodilator-treated group. Conclusion Our data suggest that dendritic cells are involved in asthmatic inflammation and that corticosteroids may downregulute the number of dendritic.
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they may play a key role in the initiation of immune responses. In the lung, dendritic cells are predominantly observed in epithelial and subcpithelial tissue of the bronch(iol)us and in the bronchus-associated lymphoid tissue [7] . Typical immunohistological features of DC are a strong major histocompatibility complex (MHC) class II(HLA-DR) expression [8] [9] [10] , long cytoplasmic extensions, and the absence or a juxtanuclear spot of acid phosphatasc. A combination of dendritic morphology and the expression of CDla is characteristic for DC [11.12] . Increased numbers of CDla ' DC and increased expression of MHC class II have been described in bronchial biopsies of asthmatic patients [13] .
Corticosteroids arc the most effective therapy for asthtna, bul their precise mechanism of action is still unclear [14] . Corticosteroids inhibit cytokine gene transcription and cytokine effects, thereby reducing chronic inflammation in asthma [14] [15] [16] [17] . To date, the effects of inhaled corticosteroids on DC in asthma are unknown. We hypothesized that the beneficial effects of corticosteroid therapy in atopic asthmatics may in part result from a downregulation of the numbers of DC. resulting in a decreased local T-ccll stimulation. Therefore we examined the distribution of the DC in the bronchial epithelium and mucosa of atopic asthmatics by immunohistochemistry. To this aim the effects of 2.5 years of double-blind treatment with bronchodilators alone or with bronchodilators plus beclomethasone dipropionate (BDP) were evaluated. The patients were randomly sampled from the Dutch chronic non-specific lung disease (CNSLD) study [18] .
Materials and methods
Patients and control subjects
Sixteen non-smoking atopic asthmatic patients (seven women, nine men. median age 43 years, range 24-61 years) were randomly sampled from the Dutch CNSLD study group [ 18.19] in two participating centres. Groningcn and Rotterdam.
The diagnosis of asthma was based on a history of attacks of breathiessness and wheezing without chronic cough or sputum production (i.e. for more than 3 months per year),according to the criteria of the American Thoracic Society [20] . Atopy was defined as a positive skin-prick test to house dust mite or at least two of 12 common aeroallergens (mean weal size > 0.7 times the histamine weal size [21] ). All patients showed airway hyperreactivity to histamine with a provocative concentration of histamine causing a 20% decrease in FEVi (PC.,,) of ^ 8tng/mL [19.21] . Patients were treated in a double-blind fashion with an inhaled /i2-agonist (terbutaline, 250 //g two puffs) plus either inhaled corticosteroid (BDP. 100//g two puffs) (BA + CS)(« = 5), an anticholinergic bronchodilator (ipratropium bromide, 20 //g two puffs) (B A + AC)(« -5) or placebo (BA +PL)(/;==6). All medication was taken four times daily. Because no significant differences were found between the BA + AC group atid the BA + PL group with regard to FEV| and PC211 the data were subsequently pooled for analysis in one bronchodilator group («^11). The fibreoptic bronchoscopy was performed at the end of the 2.5 years study in the same period (between August and December) in both centres, before breaking the code. Eight healthy non-smoking subjects (three women, five men. median age 23 years, range 19-52 years) without medication were studied as controls. All controls had a PC20 of more than 8 mg/tnL and a median FEV, of 103 (88-110) % predicted. Patient and control characteristics arc shown in Table 1 . Further details of the study methods have been described previously [19] . The study protocol was approved by the Medical Ethics Committee; all patients and controls gave written informed consent.
Bronchoscopy
Fibreoptic bronchoscopy ( Olympus model BF IT 10, Tokyo, Japan) was performed with atropine 0.5 mg intramuscularly as premedication. Terbutaline, two puffs of 250//g per Nebuhaler, was given 30 min before the procedure. The nose, throat and vocal cords were anaesthetized with topical lidocaine spray. An Olympus alligator forceps model FBI5C and the fenestrated forceps model FBI9C were used to take two biopsies from segmental and subsegmental divisions of the main bronchi.
Bronchial biopsies
Each biopsy was immediately placed in isotonic saline and frozen within 20 min in Tissue-Tek II OCT embedding medium (Miles., Naperville. Illinois. USA). Samples were stored at -80"C until use. Frozen sections (6/fm) were cut on a Reichert-Jung 2800 Frigocut cryostat. Two sections from each biopsy were placed on poly-L-Iysinecoated (Sigma Diagnostics. St Louis. MO. USA) microscopic slides. Sections were air dried for 30 min and stored at -8O'C until use.
Immunoh istodwmistry •
The following monoclonal antibodies (MoAb) were used: OKT6 (CDla) (American Type Culture Collection., Rockville. Maryland, USA), directed against the CDla 10 U
Median
Control subjects antigen of DC [ 12] ; L25, a MoAb directed against B cells and DC [13] was kindly provided by Dr T. Takami (Gifu, Japan); HLA-DR ( Central Laboratory of the Netherlands Red Cross Blood Transfusion Service (CLB), Amsterdam, the Netherlands), and biotin-conjugated HLA-DR MoAb (Becton Dickinson, San Jose, CA, USA). The MoAb staining was detected by the immuno-alkaline phosphatase anti-alkaline phosphatase (APAAP) method. The sections were fixed in acetone for 10 min at 20°C, rinsed in phosphate-buffered saline (PBS. pH 7.2) and placed in a half-automatic stainer (Shandon, Pittsburgh, PA. USA). In this stainer the slides were sequentially incubated with bovine serum albumin (BSA) 2% in PBS for lOmin, incubated with normal rabbit serum (CLB, Amsterdam, the Netherlands) for 10 min and incubated with the MoAb in the optimal dilution for 30 min at 2O''C. The optimal dilutions were determined by previous titration studies of the specific MoAb (0KT6 10 //g/mL; L25 I ^g/mL and HLA-DR 0. To establish that L25 ^ DC were also expressing HLA-DR we performed a double-labelling with L25 and biotinylated HLA-DR. The procedure followed the APAAP protocol up to the incubation with APAAP for 30 min. After rinsing in PBS and blocking with normal mouse serum (1 : 10) for lOmin, the slides were incubated for 45 min with the second MoAb biotinylated HLA-DR. Slides were rinsed in PBS and incubated with streptavidine-/? galactosidase (Biogenex, San Ramon, CA, USA) for 45 min. and rinsed again with PBS. Slides were sequentially incubated with (i galactoside (Serva. Heidelberg. Germany) which stained positive cells green, rinsed in TRIS buffer {pH 8.0) and stained with New Fuchsin, which stained L25 * cells red. Finally, the sections were rinsed in distilled water and mounted in glycerin gelatin. The immuno-double staining with L25 and HLA-DR was performed on three sections of three different patients, because of scarcity of biopsy material.
Quantification
Biopsies were coded and two sections 120 //m apart were counted in a blinded fashion for each antibody and each biopsy at a magnification of 10x40 by one person (G.M.M.) and the mean value was calculated. With an eye piece graticule the numbers of positively stained cells were counted in a zone 100//m deep in the bronchial mucosa along the length of the epithelial basement membrane (BM), which had to be covered with epithelium over at least 500//m. Cells were counted if they stained red and contained a nucleus. The cell counts were expressed as the number per unit (1 mm) of basement membrane. The (biotinylated) HLA-DR expression was scored semiquantitatively on a 0 3 scale (0 = negative; l=weak; 2 = strong; 3^ very strong). Double-stained cells L25 * and biotinylated HLA-DR^ were counted if they stained violet and contained a nucleus.
Statistical analysis
The numbers of positive cells for most of the MoAb used showed a positive skewed distribution and therefore were analysed using non-parametric statistics. Median cell counts from biopsies from asthmatics who received inhaled corticosteroids were compared with those who received only bronchodilators using the Mann-Whitney t/-test. Median cell counts from biopsies from atopic asthmatics of the bronchodilator group were compared with median cell counts of the control subjects using the AFEVi in % predicted: difference in median change (ranges) of FEV| % predicted from baseline to 2-5 years. Alog^PC^o in mg/mL: difference in median change (ranges) of logiPCio mg/mL to histamine from baseline lo 2.5 years.
Mann-Whitney L'-test. A value of F< 0.05 was considered significant.
Results
Pulmonary function data
Details of patient and pulmonary function data have been described before [18] . In short: 2^ years of inhaled BDP resulted in a significant improvement in FEV| of 14.7% of predicted compared with bronchodilator group (-3.6% of predicted. P-0.009) ( Table 2 ). Log2PC2o in the corticosteroid group improved 2.5 dose steps, compared with 0.6 dose steps in the bronchodilator group (/' = O.OI3)(Table2).
Bronchial epithelium
Some sections could not quantitatively be evaluated for bronchial epithelial infiltration because they did not show enough intact epithelium (Table 3 ). In the sections of the asthmatic patients who received bronchodilators only {n = l) the epithelitim consisted for approximately 60Vo of a monolayer and for 10% of a multilayer of partially stratified cuboidal epithelium; the epithelium of the group of corticosteroid-treated patients consisted for approximately 45% of a monolayer and for 40% of a multilayer of cuboidal epithelium. The loss of epithelium from the BM (shedding) was 30% of the total length of epithelium in the bronchodilator group whereas it was 15% in the corticosteroid group. Though there were clearly dendritic-shaped CDlaĉ ells expressing MHC class II in the epithelium of all the groups studied, differences between groups did not reach statistical significance (Table 3) .
Bronchial mucosa
The bronchial mucosa of the asthmatic patients consisted of a subepithelial cell-rich layer and a deeper cell poor layer. Higher numbers of CDla' DC were found in the bronchial mucosa of patients of the bronchodilator group (F^0.008) (Fig. I) . In addition, the numbers of L25 ' cells (Figs 1 and 2 ) and the expression of MHC class II (Fig. 1) in the bronchodilator group were higher than in the heahhy controls (Table 3 ). The doublestaining of HLA-DR and L25 showed that virtually all L25 ' DC expressed HLA-DR. The HLA-DR expression was not only confined to cells in the mucosa showing an irregular outline with marked cytoplasmic extensions (DC), but there were also other cells like lymphocytes and macrophages positive for HLA-DR. The numbers of CDla ' DC were significantly lower in the corticosteroid-treated group than in the bronchodilator group (Z'-0.008) (Fig. 1) . The number of L25ĉ ells in the corticosteroid group was also lower (median 5.7/mmBM) than in the bronchodilator group (median 10.3/mmBM), but this difference did not reach significance (P = 0.282) (Table 3) . However, a significantly lower MHC class 11 expression was found in the corticosteroid group compared with the bronchodilator group (Fig. l) (/' = 0.028).
Discu^ion
In this study we have observed that the numbers of DC in the bronchial mucosa of atopic asthmatic patients are significantly higher than in healthy control subjects and that 2.5 years of inhaled corticosteroid therapy downregulate the number of DC to normal levels, accompanied by a significantly improved FEV| and reduced hyperresponsiveness.
Our data of increased numbers of CD la"*" DC in atopic asthma are in agreement with data of a study of Bellini et al. [22] who also showed increased numbers of intraepithelial and mucosal CDla ' DC in atopic asthmatics as compared to non-asthmatic atopic controls sensitized to the same allergen. Furthermore, an increased frequency of DC has been reported in the nasal mucosa of patients with atopic rhinitis during the pollen season [23] .
Dendritic cells in the epithelium of the airways form a network [24, 25] . For primary responses they are strategically positioned to pick up inhaled antigens, migrate to regional lymph nodes and present the inhaled antigens to lymphnode T cells. For secondary responses in the mucosa local antigen presentation by DC to T cells and local activation of T cells are thought to occur as well [26] . In asthma it has been suggested that DC play a prime role in inducing cytokine production by the local activation of T cells [27.28] . In this way they are thought to act as important pro-inflammatory cells. It has indeed been demonstrated both //; vivo [29] as well as in vitro [22.30] that DC are able to activate TH. cells. The mechanisms by which DC induce the expansion of THi cells are still unclear, but some consider -despite the low production of cytokines by DC -the secretion of interleukin-1, a co-stimulator for THT cells, as important. DC might, however, also induce TH| expansion [31] . In vitro IL-12 production by DC favours such TH-1 expansion, as observed by secretion of interferon-gamma (IFN7) and immunoglobulin G^a (IgG^a) humoral responses [32] . Biopsy studies in patients with asthma have confirmed that inhaled corticosteroids reduce the number and activation of several inflammatory cells [33] [34] [35] [36] . Although this study was carried out on a limited number of patients, our data show that clinical improvement induced by local BDP administration is accompanied by significantly lower numbers of CDla^ DC and HLA-DR^ cells in the bronchial mucosa. The here described inhibitory effects of 2.5 years of corticosteroids on DC numbers and HLA-DR expression, are in agreement with data of Burke ct al. who described a reduction in RFDl ^ DC and HLA-DR expression after 3 months of budesonide in asthma [13] . Thus, long-term treatment with inhaled corticosteroids also reduces the number of DC in the bronchial mucosa. Studies in the nasal mucosa of patients with atopic rhinitis showed that 3 months of fluticasone therapy decreases the CDla"^ and HLA-DR^ cells [37] .
It may be that chemoattractive factors such as leukotriene B4 [38] , monocyte chemoat tract ant protein 1 [39] , and substance P play a role in attracting DC into the epithelium in allergic inflammation. Substance P, secreted by C-fibres was found to be a highly effective chemoattractant for DC [40] and in this way neurogetiic inflammation might contribute to the DC migration. Interestingly, corticosteroids have been reported to suppress the release of chemotactic factors from epithelial cells, indicating a possible important role of the epithelium in DC kinetics [38] under such circumstances.
In conclusion, our data show that DC numbers are elevated in atopic asthma, and can be normalized by local corticosteroid therapy. We suggest that DC may play an important role in the initiation and propagation of the asthmatic inflammation because DC are situated strategically in bronchial mucosa and DC have been described as the most potent APC population for T-cell stimulation. In this way, reduction of DC numbers after 2.5 years of corticosteroid therapy may result in a down- regulation of T-cel! activation and hence affect allergic airway inflammation.
